OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

2026-07-15 · Source: TechCrunch · Field: Science & Research — Life Sciences & Biology, Health & Medical Research, AI in Drug Discovery · Depth: Fundamental Awareness, quick

Summary

Miles Wang, an OpenAI researcher known for his work on accelerating scientific and biological discovery with AI, is departing to launch a new startup focused on AI models for drug discovery. He is reportedly in discussions to raise approximately \$200 million at a \$2 billion valuation, with Lightspeed potentially leading the funding round. Several other OpenAI researchers are expected to join the venture. The startup may concentrate on drug repurposing, finding new uses for existing or previously failed drugs, which offers a faster route to market due to established safety profiles. This initiative highlights a broader trend of significant investor interest in applying AI to life sciences, evidenced by Chai Discovery's recent \$400 million raise at a \$3.8 billion valuation and Isomorphic Labs' \$2.1 billion Series B.

Key takeaway

For investors evaluating new ventures in biotech or AI, Miles Wang's \$2 billion startup and recent large funding rounds for Chai Discovery and Isomorphic Labs signal robust market confidence in AI-driven drug discovery. You should prioritize startups focusing on drug repurposing, as this strategy offers a significantly faster path to revenue by utilizing existing safety-tested compounds. Consider the founder's background in AI research as a key indicator of potential.

Key insights

OpenAI researcher Miles Wang is launching an AI drug discovery startup, attracting significant investor interest in the field.

Principles

• Investor interest in AI for life sciences is high.
• Drug repurposing offers faster market entry.
• AI can accelerate scientific and biological discovery.

In practice

• Focus AI on drug repurposing for speed.
• Utilize AI for molecular interaction prediction.

Topics

• AI Drug Discovery
• Startup Funding
• Miles Wang
• OpenAI Researchers
• Drug Repurposing
• Life Sciences AI

Best for: Investor, Entrepreneur, Director of AI/ML

Related on AIssential

• Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma — AI-driven platforms are accelerating drug discovery by precisely predicting and reprogramming molecular interactions.
• He Raised $70M to Cure Every Disease With AI — AI agents, particularly specialized models, significantly accelerate scientific discovery by removing human talent bottlenecks and enabling high-throughput reasoning.
• Exclusive: Fathom raises $47M, blending AI and physics in drug discovery - Endpoints News — Fathom Therapeutics combines AI and physics-based simulations to accelerate drug discovery.
• DeepMind spinout Isomorphic Labs raises $2.1bn — AI-driven drug discovery benefits from specialized teams and distinct corporate structures.
• Reed Jobs would rather talk about curing cancer than his last name — Yosemite leverages a hybrid funding model and AI to accelerate oncology drug discovery from early academic research.
• Graph Therapeutics brings total funding to over $10M to advance precision immunology — AI-powered analysis of live patient cells, multi-omics data, and functional biology decodes immune dysfunction for precision immunology.

See Counsel's argued verdicts on the open AI decisions leaders are weighing →

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by TechCrunch.